Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01030432 · ClinicalTrials.gov registry record · Phase 2
Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 285
- Enrollment target
NCT01030432: Completed Phase 2 study, sponsored by Bristol-Myers Squibb.
NCT01030432 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 285 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (114% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01030432, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 285 participants
- Enrollment target
Study Summary
The purpose of this study is to identify one or more doses of BMS-650032 that, when used in combination with pegylated-interferon alpha and ribavirin are safe and demonstrate sufficient activity against hepatitis C virus (Genotypes 1 and 4).
Interventions
- DRUG Placebo
- DRUG BMS-650032
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 285 participants |
| Start Date | 2010-02 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
What the finished NCT01030432 record still lists
NCT01030432 is an interventional study that assigns participants to a tested intervention. The registered 285 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (114% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01030432 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01030432 about?
NCT01030432 is a clinical study titled "Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin". The purpose of this study is to identify one or more doses of BMS-650032 that, when used in combination with pegylated-interferon alpha and ribavirin are safe and demonstrate sufficient activity against hepatitis C virus (Genotypes 1 and 4).
What is the current status of trial NCT01030432?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 285 participants. The study started on 2010-02. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01030432?
The interventions under investigation include: Placebo (DRUG), BMS-650032 (DRUG).
Who is sponsoring clinical trial NCT01030432?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01030432's enrollment target sits among peer trials
285 192nd of 2000 higher than 1,806 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03412877 · 285 participants · Phase 2
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
- NCT04537936 · 285 participants · NA
Psychotherapy Intervention for Latinos With Adv Cancer
- NCT04965675 · 285 participants · Phase 3
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
- NCT05320835 · 285 participants · NA
A Setting Focus Overdose Prevention Intervention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia